Table 1. Baseline characteristics of the patient groups.
| Parameters | Group 1 (with OAB) (n = 177) | Group 2 (without OAB) (n = 203) | p value |
| Age (years) | 66.2 ± 10.2 | 58.5 ± 6.7 | < 0.001 |
| Gender | 0.321 | ||
| Male, n (%) | 78 (44.1%) | 98 (48.3%) | |
| Female, n (%) | 99 (55.9%) | 105 (51.7%) | |
| Diabetes mellitus, n (%) | 98 (55.3%) | 63 (31%) | 0.003 |
| Hypertension, n (%) | 65 (36.7%) | 68 (33.4%) | 0.612 |
| SBP (mmHg) | 127.1 ± 8.3 | 126.3 ± 6.2 | 0.592 |
| DBP (mmHg) | 72.2 ± 5.6 | 73.1 ± 4.9 | 0.643 |
| Dyslipidemia, n (%) | 67 (37.8%) | 87 (42.8%) | 0.572 |
| Smoker, n (%) | 104 (58.7%) | 68 (13.8%) | < 0.001 |
| BMI (kg/m2) | 29.7 ± 3.6 | 23.6 ± 4.2 | < 0.001 |
| Heart rate, bpm | 74 ± 15 | 83.4 ± 12 | < 0.001 |
| Hemoglobin, g/dL | 13.4 ± 1.5 | 14.6 ± 3.2 | 0.238 |
| Creatinine (mg/dL) | 0.82 ± 0.13 | 0.77 ± 0.32 | 0.082 |
| eGFR (mL/min/1.73 m2) | 77.2 ± 13.4 | 82.5 ± 12.5 | 0.921 |
| Total cholesterol (mg/dl) | 196 ± 35 | 174 ± 55 | 0.118 |
| Triglyceride (mg/dl) | 173 ± 96 | 144 ± 74 | 0.125 |
| HDL-cholesterol (mg/dl) | 39 ± 6 | 43 ± 5 | 0.152 |
| LDL-cholesterol (mg/dl) | 126 ± 37 | 108 ± 32 | 0.312 |
| OAB-V8 | 21.21 ± 3.62 | 6.52 ± 2.94 | < 0.001 |
| SYNTAX score | 25.4 ± 4.2 | 18.3 ± 3.4 | < 0.001 |
| Medications | |||
| ASA n (%) | 94 (53.1%) | 105 (51.7%) | 0.587 |
| Clopidogrel | 54 (30.5%) | 61 (30.0%) | 0.862 |
| Ticagrelor | 18 (10.1%) | 26 (12.8%) | 0.503 |
| Prasugrel | 21 (11.8%) | 17 (8.3%) | 0.397 |
| ACE inhibitors/ARB, n (%) | 60 (33.8%) | 76 (37.4%) | 0.428 |
| β-blockers, n (%) | 39 (22%) | 57 (28%) | 0.281 |
| Calcium channel blockers | 12 (6.7%) | 13 (6.4%) | 0.934 |
| Statins, n (%) | 45 (25.4%) | 64 (31%) | 0.354 |
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OAB, overactive bladder; OAB-V8, overactive bladder-validated 8; SBP, systolic blood pressure.